Back to VRTX Stock Lookup

Vertex Pharma (VRTX) – Company Press Releases

May 17, 2015 01:32 PM New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM (lumacaftor/ivacaftor) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation
May 13, 2015 04:01 PM Vertex to Present at the UBS Healthcare Conference on May 19
May 12, 2015 04:15 PM Food and Drug Administration Advisory Panel Voted 12 to 1 to Recommend Approval of ORKAMBI™ (lumacaftor/ivacaftor) to Treat People with Cystic Fibrosis Ages 12 and Older Who Have Two Copies of the F
Apr 29, 2015 04:01 PM Vertex Reports First Quarter 2015 Financial Results
Apr 9, 2015 04:01 PM Vertex to Announce First Quarter 2015 Financial Results on April 29
Mar 23, 2015 07:45 AM Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Mar 18, 2015 07:46 AM Vertex Receives U.S. Food and Drug Administration Approval of KALYDECO® (ivacaftor) for Children with Cystic Fibrosis Ages 2 to 5 who have Specific Mutations in the CFTR Gene

Back to VRTX Stock Lookup